title: Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting.
abstract: Transepithelial transport of antigens and pathogens across the epithelial barrier by M cells may be a prerequisite for induction of mucosal immunity in the intestine. Efficient transport of antigens and pathogens requires adherence to M cell apical surfaces. Coupling of antigen-containing particles to the pentameric binding subunit of cholera toxin (CTB) has been proposed as a means for increasing antigen uptake because the CTB receptor, ganglioside GM1, is a glycolipid present in apical membranes of all intestinal epithelial cells. To test the accessibility of enterocyte and M cell membrane glycolipids to ligands in the size ranges of viruses, bacteria, and particulate mucosal vaccines, we analyzed binding of CTB probes of different sizes to rabbit Peyer's patch epithelium. Soluble CTB-fluorescein isothiocyanate (diameter 6.4 nm) bound to apical membranes of all epithelial cells. CTB coupled to 14 nm colloidal gold (final diameter, 28.8 nm) failed to adhere to enterocytes but did adhere to M cells. CTB-coated, fluorescent microparticles (final diameter, 1.13 microns) failed to adhere to enterocytes or M cells in vivo or to well-differentiated Caco-2 intestinal epithelial cells in vitro. However, these particles bound specifically to GM1 on BALB/c 3T3 fibroblasts in vitro and to undifferentiated Caco-2 cells that lacked brush borders and glycocalyx. Measurements of glycocalyx thickness by electron microscopy suggested that a relatively thin (20 nm) glycocalyx was sufficient to prevent access of 1-micron microparticles to glycolipid receptors. Thus, the barrier function of the intestinal epithelial cell glycocalyx may be important in limiting microbial adherence to membrane glycolipids, and in CTB-mediated targeting of vaccines to M cells and the mucosal immune system.
authors.affiliation: Department of Pediatrics, Harvard Medical School, Children's Hospital, Boston, Massachusetts 02115, USA.
authors.forename: A
authors.initials: A
authors.lastname: Frey
authors.forename: K T
authors.initials: KT
authors.lastname: Giannasca
authors.forename: R
authors.initials: R
authors.lastname: Weltzin
authors.forename: P J
authors.initials: PJ
authors.lastname: Giannasca
authors.forename: H
authors.initials: H
authors.lastname: Reggio
authors.forename: W I
authors.initials: WI
authors.lastname: Lencer
authors.forename: M R
authors.initials: MR
authors.lastname: Neutra
mesh_terms: D016475:3T3 Cells; D000284:Administration, Oral; D000818:Animals; D001422:Bacterial Adhesion; D018938:Caco-2 Cells; D002454:Cell Differentiation; D002462:Cell Membrane / Q000378:metabolism; D004847:Epithelial Cells; D005260:Female; D005677:G(M1) Ganglioside / Q000378:metabolism; D019276:Glycocalyx / Q000502:physiology*; D006801:Humans; D018928:Immunity, Mucosal; D007422:Intestines / Q000166:cytology*; D051379:Mice; D008807:Mice, Inbred BALB C; D011817:Rabbits; D011956:Receptors, Cell Surface / Q000378:metabolism; D012542:Scattering, Radiation; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D011956:Receptors, Cell Surface; D014612:Vaccines; C023552:choleragen receptor; D005677:G(M1) Ganglioside